{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-022267","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2025-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.535774+00:00","generated_at":"2026-05-19T11:59:16.881908+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Ionis CDO Richard Geary retiring Jan 2026; Holly Kordasiewicz to succeed","bullets":["Richard Geary, EVP & chief development officer, will retire effective January 2026 after 30 years at Ionis.","Holly Kordasiewicz, currently SVP neurology, to become EVP & chief development officer in January 2026.","Geary led 50+ IND submissions and 6 FDA/EU approvals including TRYNGOLZA; will stay as strategic consultant in 2026.","Kordasiewicz has 20 years R&D experience and played key role in QALSODY and IONIS-MAPT Rx Alzheimer's program."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-022267","json":"https://secwatch.observer/filing/0001140361-25-022267.json","markdown":"https://secwatch.observer/filing/0001140361-25-022267.md","text":"https://secwatch.observer/filing/0001140361-25-022267.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036125022267/0001140361-25-022267-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036125022267/ef20050532_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T11:59:16.881908+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b57f8b2033","claim":"Holly Kordasiewicz was appointed as executive vice president and chief development officer at IONIS PHARMACEUTICALS INC.","evidence_excerpt":"On June 12, 2025, the Company issued a press release announcing that Holly Kordasiewicz, Ph.D., currently senior vice president, neurology, will succeed Dr. Richard Geary Ph.D. in the role of executive vice president and chief development officer beginning in January 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/874015/000114036125022267/0001140361-25-022267-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"executive vice president and chief development officer"}],"fact_type":"executive_change"},{"claim_id":"da6ae1df19","claim":"Richard Geary retired as executive vice president and chief development officer at IONIS PHARMACEUTICALS INC.","evidence_excerpt":"On June 12, 2025, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Richard Geary Ph.D., executive vice president and chief development officer, will retire effective January 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/874015/000114036125022267/0001140361-25-022267-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"executive vice president and chief development officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}